Nasdaq · Healthcare

Editas Medicine, Inc. (EDIT)

As-reported financials and recent SEC filings for Editas Medicine, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$40.5M

Net income

$-160.1M

Net margin

—

Diluted EPS

$-1.80

ROE

-586.6%

P/E (TTM)

—

Market cap

—

Debt / equity

2.0×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$40.5M	$32.3M	$78.1M	$19.7M	$25.5M
Gross profit	—	—	—	—	—
Operating income	$-160.0M	$-251.2M	$-169.2M	$-225.9M	$-193.1M
Net income	$-160.1M	$-237.1M	$-153.2M	$-220.4M	$-192.5M
Diluted EPS	$-1.80	$-2.88	$-2.02	$-3.21	$-2.85

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-22

42026-06-22

42026-06-22

42026-06-22

42026-06-22

8-K2026-06-18

42026-06-05

42026-06-05

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on EDIT

Search Editas Medicine, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.